Experimental HIV vaccine shows promise in early safety trial
NCT ID NCT05781542
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial tested a DNA vaccine designed to teach the immune system to recognize HIV. 46 healthy adults received the vaccine with or without a protein boost. The main goal was to see if it is safe and whether it triggers the right immune cells. Results will help decide if further studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DNA vaccine (sD-NP-GT8) plus IL-12, with or without an HIV protein boost (Trimer 4571) and an adjuvant (3M-052-AF)
What this could lead to
If successful, this could point toward a vaccine that trains the immune system to make special antibodies that block many HIV strains.
What could go wrong
This is an early Phase 1 trial with only 46 healthy volunteers, so it is mainly checking safety and basic immune responses. It is far too early to know if it will actually prevent HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS (Site ID: 31788)
Birmingham, Alabama, 35294, United States
-
Bridge HIV CRS
San Francisco, California, 94102, United States
-
Brigham and Women's Hospital Vaccine CRS [30007]
Boston, Massachusetts, 02115, United States
-
CAPRISA eThekwini CRS
Durban, KwaZulu-Natal, 4013, South Africa
-
Durban Adult HIV CRS
Durban, KwaZulu-Natal, South Africa
-
Groote Schuur HIV CRS (Site ID: 31708)
Cape Town, Western Cape, 7925, South Africa
-
San Francisco Vaccine and Prevention CRS
San Francisco, California, 94102, United States
-
Soweto HVTN CRS
Johannesburg, Gauteng, South Africa